atorvastatin has been researched along with Cardiovascular Stroke in 368 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.09) | 18.2507 |
| 2000's | 183 (49.73) | 29.6817 |
| 2010's | 159 (43.21) | 24.3611 |
| 2020's | 22 (5.98) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, J; Choi, JH; Choi, KH; Choi, SH; Guallar, E; Gwon, HC; Hahn, JY; Kang, D; Kang, M; Kim, J; Lee, JM; Park, H; Park, TK; Song, YB; Yang, JH | 1 |
| Li, Z; Tu, Y; Zhang, J; Zhang, M; Zhou, Q; Zong, W | 1 |
| Angermann, C; Armitage, J; Baigent, C; Barter, P; Baxter, A; Blaustein, R; Bowman, L; Braunwald, E; Brenner, S; Cannon, C; Chen, F; Chen, Y; Chen, Z; Collins, R; Dayanandan, R; DeLucca, P; Ertl, G; Fabbri, G; Fajardo-Moser, M; Goodenough, R; Goto, S; Gray, A; Hao, D; Haynes, R; Herrington, W; Hill, M; Hopewell, JC; Knott, C; Landray, M; Lay, M; Liu, J; Lucci, D; Macdonnell, S; Maggioni, A; Mihaylova, B; Mitchel, Y; Mosegaard, S; Murphy, K; Sammons, E; Stevens, W; Tobert, J; Valdes-Marquez, E; Wallendszus, K; Wanner, C; Wincott, E; Wiviott, S; Wuhan, B; Zhang, H | 1 |
| Alonso Garcia, A; Andres, V; Barczi, G; Baviera, M; Beghi, E; Bejot, Y; Bhatt, DL; Bueno, H; Castellano, JM; Colivicchi, F; Collier, T; Cordero, A; Di Fusco, SA; Doehner, W; Domingo-Fernández, A; Ecarnot, F; Fernandez Alvira, JM; Fernandez Ferro, J; Fernandez-Ortiz, A; Foresta, A; Fuster, V; Ibañez, B; Kasprzak, M; Linhart, A; Lopez, N; Lozano, I; Lubanda, JC; Marin Ortuño, F; Merkely, B; Meyer, A; Ojeda-Fernandez, L; Owen, R; Perel, P; Pocock, SJ; Ponikowski, P; Proietti, M; Quesada, AJ; Rodriguez-Manero, M; Roncaglioni, MC; Sanchez, PL; Schiele, F; Schoos, MM; Simon, T; Van de Werf, F; Vazquez Rodriguez, JM; Vivas, D | 1 |
| Chen, H; Chen, Z; Guo, J; Liu, H; Ma, Y; Peng, X; Wang, Q; Zheng, Z; Zhu, J | 1 |
| Ahn, CM; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yang, TH; Yoon, J | 1 |
| Chen, G; Gong, Z; Hu, M; Huang, P; Jiang, W; Jin, C; Li, X; Ning, Y; Qian, H; Tang, R; Wu, C; Xiong, Y; Xu, J; Yang, Y; Zhang, L | 1 |
| Huang, C | 1 |
| Gómez-Flores, SS; Medina-Romero, J; Reyes-Álvarez, FJ; Toledo-Salinas, O | 1 |
| Dong, H; Hu, X; Li, G; Liang, W; Lin, Y; Lu, H; Wang, W; Yu, B; Zhang, H; Zhou, L; Zhou, Y | 1 |
| Ahn, CM; Cho, HJ; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yoon, J | 1 |
| Liu, ZL; Zeng, HT; Zhang, ZX; Zhao, M; Zhong, SM | 1 |
| Cummings, JL; Ginsberg, HD; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, N | 1 |
| Akyürek, F; Altunkeser, BB; Ateş, MS; Aydoğan, C; Aygül, N; Demir, K; Kırık, EC; Öztürk, B; Tezcan, H; Tunçez, A; Yalçın, U | 1 |
| Bi, G; Cao, B; Wang, Y | 1 |
| Banerjee, B; Bose, PK; Chakraborty, S; Kar, A; Mahapatra, T; Manna, K; Paul, S; Rana, MS; Roy, A; Roy, D | 1 |
| Al-Rashid, F; Dykun, I; Hendricks, S; Jánosi, RA; Mahabadi, AA; Rassaf, T; Totzeck, M; Wiefhoff, D | 1 |
| Chen, X; Ding, S; Wu, S; Xu, S | 1 |
| Collinson, P; Kiely, P | 1 |
| Hoang, T; Kim, J | 1 |
| Bai, L; Cui, XR; Wang, D; Yang, XH; Zhang, JD | 1 |
| Handayani, W; Yogiarto, M | 1 |
| Borovac, JA; Bozic, J; D'Amario, D; Glavas, D; Kumric, M; Leth-Olsen, M; Schwarz, K | 1 |
| Bittner, V; Brown, TM; Colantonio, LD; Glasser, SP; Huang, L; Monda, KL; Muntner, P; Rosenson, RS; Serban, MC; Taylor, B | 1 |
| Kilit, C; Koçak, FE; Paşalı Kilit, T | 1 |
| Bittner, V; Brown, TM; Dai, Y; Farkouh, ME; Mefford, M; Monda, KL; Muntner, P; Rosenson, RS; Taylor, B; Zhao, H | 1 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Chen, L; Huang, X; Li, R | 1 |
| Cheng, J; Hu, X; Li, C | 1 |
| Appleby, C; Banning, AP; Buszman, P; Cavalcante, R; Collet, C; Cruz-Gonzalez, I; Davies, J; De Maria, GL; de Vries, T; Dudek, D; Ej West, N; Escaned, J; Farooq, V; Fath-Ordoubadi, F; Goicolea, J; Hanratty, C; Hildick-Smith, D; Hoole, SP; Iñiguez, A; Kappetein, AP; Lesiak, M; Morel, MA; Moreno, R; Ochala, A; Onuma, Y; Piek, JJ; Ryan, N; Sabate, M; Serruys, PW; Stables, RH; Taggart, DP; Uren, N; van Es, GA; van Geuns, RJ; van Mieghem, N; Walsh, S; Zaman, A; Zueco, J | 1 |
| Ferreira, J; Giugliano, RP; Huber, K; Keech, A; Lewis, BS; Murphy, SA; Pedersen, TR; Pineda, AL; Sabatine, MS; Sever, PS; Somaratne, R; Tokgozoglu, SL | 1 |
| Fernando, T; Kang, Q; Li, X; Wan, Z; Yang, M | 1 |
| Liu, G; Yang, C; Yang, H; Yang, P; Yang, S; Zhao, D; Zheng, H | 1 |
| Chen, L; Cui, Y; Jiang, J; Liu, L; Wang, K; Zhang, X | 1 |
| Ahmed, LA; Attalla, DM; Khattab, MM; Zaki, HF | 1 |
| Fei, MY; Hu, GP; Liu, ZJ; Shi, QX; Sun, F; Yin, Z | 1 |
| Brown, TM; Carson, AP; Colantonio, LD; Dai, Y; Farkouh, ME; Giustino, G; Monda, KL; Muntner, P; Rosenson, RS | 1 |
| Bible, PW; Guo, F; Guo, M; Liu, J; Shi, D; Shi, J; Tian, Y; Wang, C; Wang, P; Wei, L; Yang, M | 1 |
| Chae, SC; Cho, MC; Choi, BG; Choi, CU; Choi, JY; Hwang, SY; Jang, WY; Jeong, MH; Kim, CJ; Kim, DY; Kim, EJ; Kim, HS; Kim, JW; Kim, W; Kim, YJ; Lee, S; Na, JO; Park, CG; Park, EJ; Rha, SW; Seo, HS | 1 |
| Aquino, M; Baber, U; Barman, N; Camaj, A; Chandrasekhar, J; Claessen, B; Dangas, G; Faggioni, M; Farhan, S; Guedeney, P; Kalkman, DN; Kini, A; Kovacic, JC; Mehran, R; Moreno, P; Shah, S; Sharma, S; Sorrentino, S; Sweeny, J; Vijay, P; Vogel, B | 1 |
| De Servi, S; Leoncini, M; Toso, A | 1 |
| Chen, G; Cheng, K; Huang, P; Jin, C; Li, Q; Qian, H; Qian, L; Tian, X; Wang, L; Xiong, Y; Xu, J; Yang, Y; Yu, Y | 1 |
| Hu, MJ; Huang, PS; Jin, C; Li, Q; Liu, JD; Qian, L; Tian, XQ; Xiong, YY; Xu, J; Xu, JY; Yang, YJ | 1 |
| Qu, X; Wang, Q; Yi, X; Zheng, L | 1 |
| Boon, RA; Pham, TP | 1 |
| Bittner, V; Colantonio, LD; Dai, Y; Jaeger, BC; Kilgore, ML; Levitan, EB; Mefford, MT; Monda, KL; Muntner, P; Rosenson, RS; Woodward, M | 1 |
| Jing, LM; Li, H; Liu, HL; Luo, JP; Shen, ZQ; Yang, SL; Yang, Y | 1 |
| Flores, RM; Kanth, R; Shah, MS | 1 |
| Branny, M; Hájek, P; Malý, M; Martinkovičová, L; Tesař, D; Tomašov, P; Veselka, J; Zemánek, D | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| D'Ettorre, A; Macchia, A; Mariani, J; Romero, M; Tognoni, G | 1 |
| Chen, M; Li, H; Wang, Y | 1 |
| Wu, du C | 1 |
| Dong, QT; Gao, RL; Geng, YJ; Gersh, BJ; He, ZX; Lu, MJ; Qian, HY; Qiao, SB; Shen, R; Song, L; Yang, YJ; Zhao, SH | 1 |
| An, Z; Dong, N; Ge, LL; He, YQ; Li, SM; Yang, G; Zhang, WQ | 1 |
| Biondi-Zoccai, G; Calcagno, S; Canali, E; Conti, G; Fedele, F; Lucisano, L; Mancone, M; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Abdollahi, A; Meysamie, A; Nafasi, L; Rahmani, R; Salari, A; Shafiee, A | 1 |
| Jiang, X; Qu, Z; Tian, Y; Xu, H | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Guay, J; Ochroch, EA | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S | 1 |
| Chen, X; Fei, X; He, F; Hu, Y; Lou, Y; Wang, S; Yang, R; Ye, H | 1 |
| He, GX; Liu, XL; Xu, HP; Zhao, XJ | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Hovingh, GK; Laskey, R; Vogt, L; Waters, DD | 1 |
| Dicker, D; Elis, A; Gevrielov-Yusim, N; Goldenberg, I; Klempfner, R; Kopel, E; Matetzky, S; Pereg, D | 1 |
| Liu, X; Qu, Y; Shen, H; Xia, J | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL | 1 |
| Dong, QT; Jin, C; Li, N; Qian, HY; Wang, H; Wang, TJ; Wang, XM; Yang, YJ; Zhang, Q | 1 |
| Asrar Ul Haq, M; Mutha, V; Rudd, N; Subiakto, I; Van Gaal, WJ | 1 |
| Belló-Klein, A; Lehnen, AM; Lehnen, TE; Machado, UF; Markoski, MM; Schaan, B; Tavares, AM | 1 |
| Chitose, T; Hokamaki, J; Ogawa, H; Sakamoto, K; Shimomura, H; Shiraishi, S; Sugiyama, S; Tsunoda, R; Yamashita, T; Yamashita, Y | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| French, BA; Linden, J; Tian, Y; Yang, Z | 1 |
| Dohi, T | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Boekholdt, SM; Fayyad, R; Hovingh, GK; Laskey, R; Pedersen, TR; Stoekenbroek, RM; Tikkanen, MJ | 1 |
| Cui, W; Gao, H; Hu, H; Li, B; Li, X; Wang, Y; Zhang, H; Zhao, Z | 1 |
| Altunkeser, BB; Aydin, MU; Aygul, N; Taner, A; Unlu, A | 1 |
| Briguori, C; Condorelli, G; Napolitano, G; Quintavalle, C | 1 |
| Battler, A; Bental, T; Dadush, O; Eisen, A; Kornowski, R; Leshem-Lev, D; Lev, EI; Mager, A; Orvin, K; Rechavia, E; Yavin, H | 1 |
| Guo, X; Huang, X; Wang, Q | 1 |
| Chang, SA; Choe, YH; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kim, EK; Lee, SC; Lee, SH; Song, YB | 1 |
| Phongtuntakul, B; Tungsubutra, W | 1 |
| Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC | 1 |
| Petruccelli, S; Rebelos, E; Rosada, J; Taddei, M | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Gandhi, HP; Patel, SS; Rathod, SP; Trivedi, JI; Variya, BC | 1 |
| Barbarash, O; Belik, E; Dyleva, Y; Gruzdeva, O; Karetnikova, V; Uchasova, E | 1 |
| Ahmed, Z; Bajwa, A; Bhardwaj, B; Laster, SB; Magalski, A | 1 |
| Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Konstantara, F; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tziomalos, K | 1 |
| Chen, H; Dai, G; Deng, Y; Gao, J; Li, Y; Luo, R; Wang, Y; Wu, X; Xu, Q; Yuan, W | 1 |
| Burzyńska, B; Dłużniewski, M; Góra, M; Maciejak, A; Opolski, G; Pawlak, M; Piniewska-Juraszek, J; Sitkiewicz, D; Sygitowicz, G | 1 |
| Hikichi, Y; Inoue, T; Inoue, Y; Kawasaki, T; Kodama, K; Komatsu, A; Komoda, H; Mine, D; Natsuaki, M; Node, K; Oyama, J; Sakuma, M; Shibata, Y; Shimomura, M; Takeuchi, M; Toyoda, S; Yamagishi, S; Yamamoto, Y | 1 |
| Liu, W; Wu, S; Zhou, Y | 1 |
| Chen, H; Li, L; Liu, T; Su, Q; Wang, J; Wang, XT; Zhou, Y | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Chen, LZ; Huang, XS; Li, R; Zhao, SP | 1 |
| Füessl, HS; Stiefelhagen, P | 1 |
| Cheng, W; Hu, H; Li, X; Shi, Y; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J | 1 |
| Boekholdt, SM; Colhoun, HM; Davis, BR; Kaasenbrood, L; Livingstone, SJ; Poulter, NR; Pressel, SL; Sever, PS; van der Graaf, Y; Visseren, FL | 1 |
| Chu, Y; Hao, H; Hu, S; Joerg, H; Li, B; Liu, Z; Sang, C; Xia, J; Xu, D; Xu, J | 1 |
| Briguori, C; Calabrò, P; Condorelli, G; De Caterina, R; Madonna, R; Quintavalle, C; Salomone, M; Zimarino, M | 1 |
| Cheng, WP; Chua, SK; Lo, HM; Lu, MJ; Shyu, KG; Wang, BW | 1 |
| Cao, JJ; Guerci, A; Pollack, S; Reichek, N; Roth, M; Waheed, S | 1 |
| Eatough, R; Harada-Shiba, M; Kamiya, C; Makino, H; Ogura, M; Perrone, G; Soran, H; Stefanutti, C; Yoshimatsu, J | 1 |
| Al Danaf, J; Duffy, D; Panakos, A; Ragupathi, L; Valentino, M; Whellan, D | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Carvalho Sposito, A; da Mota Silveira-Filho, L; de Souza Vilarinho, KA; Diógenes de Carvalho, D; Galluce Torina, A; Martins de Oliveira, PP; Pereira do Carmo, HR; Petrucci, O; Reichert, K | 1 |
| Alboim, C; Almeida, AP; Barbosa, RR; Berwanger, O; Carmona, MJ; Damiani, L; de Barros E Silva, PG; de Oliveira Filho, JB; Devereaux, PJ; Dracoulakis, MD; Figueiredo, EL; Filho, HV; Gonzales, B; Hajjar, LA; Ikeoka, DT; Kodama, AA; Kruel, CD; Lopes, RD; Maia, LN; Paisani, D; Precoma, DB; Saraiva, JF; Soares, RM | 1 |
| Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Thayssen, P; Veien, K | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Messerli, FH; Waters, DD | 1 |
| Braunwald, E; Cannon, CP; Daga, S; Dalby, AJ; Eisen, A; Goodrich, EL; Im, K; Lukas, MA; O'Donoghue, ML; Spinar, J; Steen, DL; Zhou, J | 1 |
| Duda, M; Maczewska, J; Maczewski, M | 1 |
| Bellesi, S; Biasucci, LM; Brugaletta, S; Crea, F; Galiuto, L; Garramone, B; Giannico, MB; Leone, AM; Leone, G; Liuzzo, G; Niccoli, G; Perfetti, M; Porto, I; Rebuzzi, AG; Rutella, S; Zaccone, V | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Dobson, R | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M | 1 |
| Basart, DC; Defesche, JC; Heeringa, J; Kastelein, JJ; Lansberg, PJ; Liem, AH; Oosterveer, DM; Sijbrands, EJ; Versmissen, J; Witteman, JC; Yazdanpanah, M | 1 |
| Fu, SY; Li, WM; Li, ZQ; Tang, Q; Wang, LF | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Akioka, H; Anan, F; Hara, M; Iwao, T; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Yonemochi, H; Yufu, K | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E; Veglia, F | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ | 3 |
| Li, J; Li, X; Li, ZQ; Liu, YY; Pan, W; Sun, YM; Tian, Y; Wang, LF | 1 |
| Boyle, A; Connelly, KA; Gilbert, RE; Kelly, D; Kompa, A; Krum, H; Martin, JH; Zhang, Y | 1 |
| Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Strandberg, TE; Tikkanen, MJ | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H | 1 |
| Akdemir, R; Karakurt, O | 1 |
| Colonna, G; Di Sciascio, G; Gaspardone, A; Montinaro, A; Pasceri, V; Patti, G | 1 |
| Briguori, C; Castelli, A; Chieffo, A; Colombo, A; Focaccio, A; Golia, B; Montorfano, M; Mussardo, M; Ricciardelli, B; Visconti, G | 1 |
| Adlová, R; Hájek, P; Malý, M; Martinkovicová, L; Tesar, D; Veselka, J; Zemánek, D | 1 |
| Abad, L; Andres Domingo, M; de Luis, D; Duenas-Laita, A; Gonzalez Sagredo, M; Pérez Castrillón, JL; San Miguel, A; Vega, G | 1 |
| Chakrabarti, D; Saikia, PK | 1 |
| Aikawa, E; Figueiredo, JL; Hembrador, S; Keliher, E; Kelly, K; Libby, P; Nahrendorf, M; Panizzi, P; Weissleder, R; Zhang, H | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Valles, J | 1 |
| Cater, NB; Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K | 1 |
| Liang, Y; Shen, F; Wang, A; Wang, J | 1 |
| Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Tuttle, KR | 1 |
| Colivicchi, F; Genovesi Ebert, A; Melina, G; Mocini, D; Santini, M; Strano, S; Tubaro, M; Uguccioni, M | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Kim, YH; Lim, DS; Park, JH; Park, SM; Shim, WJ | 1 |
| Chapman, RH; Roberts, CS; Yeaw, J | 1 |
| Arrospide, A; Caro, J; Mar, J; Rejas-Gutiérrez, J; Vivancos-Mora, J | 1 |
| Bahl, A; Khullar, M; Poduri, A; Sehrawat, BS; Sharma, Y; Talwar, KK | 1 |
| Bonassin, F; Schneemann, M; Wyss, C | 1 |
| Alfano, G; Chello, M; Covino, E; Di Sciascio, G; Gatto, L; Miglionico, M; Patti, G | 1 |
| Ducharme, A; Dupuis, J; Jiang, BH; Martin, JG; Sauvageau, S; Shi, Y; Tardif, JC | 1 |
| Abdel-Aziz, NA; Abo-Elmatty, DM; Ghattas, MH; Tawfik, MK | 1 |
| Di Sciascio, G; Melfi, R; Nusca, A; Patti, G | 1 |
| Holman, JR; Jamieson, B; Lin, V | 1 |
| Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL | 1 |
| Holme, I; Kvien, TK; Pedersen, TR; Semb, AG | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Schunn, H | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Tedeschi, D; Toso, A | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Aicher, A; Dimmeler, S; Fichtlscherer, S; Schmidt-Lucke, C; Schultheiss, HP; Tschöpe, C; Zeiher, AM | 1 |
| Chen, WQ; Ge, ZM; Geng, J; Ji, XP; Ren, SD; Wu, TT; Yu, XL; Zhang, HJ; Zhong, L | 1 |
| Arsenault, BJ; Bao, W; Barter, P; Deedwania, P; DeMicco, DA; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Preston, GM; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Guan, Y; Li, N; Su, G; Wang, L; Wang, S; Xie, W; Zhang, D; Zhao, P | 1 |
| Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C | 1 |
| Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R | 1 |
| Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Patti, G | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Korkor, MT; Liu, B; Liu, JY; Song, XJ; Wei, Q; Yang, CY; Yang, P | 1 |
| Bi, Q; Bolli, R; Dawn, B; Hunt, G; Peng, Y; Sanganalmath, SK; Sato, H; Shirk, G; Tang, XL; Vincent, RJ | 1 |
| Cai, A; Dai, G; Dong, Y; Huang, Y; Jiang, Z; Kuang, J; Liao, X; Mai, W; Qiu, R; Rao, S; Song, Y; Zheng, D | 1 |
| Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T | 1 |
| Ahn, KJ; Choi, JH; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jo, SH; Kim, HJ; Lee, KH; Lee, S; Lee, SH; Song, YB | 1 |
| Krasznai, Z; Toth, P | 1 |
| Schaefer, JR | 1 |
| Cai, A; Dai, G; Huang, Y; Kuang, J; Mai, W; Qiu, R; Song, Y | 1 |
| Lee, T | 1 |
| Doevendans, PA; Eefting, FD; Goumans, MJ; Post, MC; Post, S; Rensing, BJ; Stella, PR; van den Branden, BJ; van Es, HW; Wildbergh, TX | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Bonaca, MP; Bui, AH; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Li, X; Wang, X; Wang, Y; Wu, W; Yang, Z | 1 |
| Cao, Y; Fan, Y; Huang, Y; Yang, S | 1 |
| Doevendans, PA; Goumans, MJ; Pasterkamp, G; Post, S; Rensing, BJ; van den Broek, AJ | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Puri, R; Tuzcu, EM | 1 |
| Cai, A; Dong, Y; Feng, Y; Huang, Y; Mai, W; Qiu, R; Rao, S; Yu, D; Zheng, D; Zhou, Y | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Ahmed, W; Ali, IS; Ali, SH; Azam, M; Niazi, AK; Niazi, SH; Qamar, R; Riaz, M; Sadeque, A; Younas, A | 1 |
| Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A | 1 |
| Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A | 1 |
| Jonasson, L; Linderfalk, C; Olsson, AG; Schwartz, GG | 1 |
| Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A | 1 |
| Seeger, JD | 1 |
| Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Symeonidis, AN | 1 |
| Bell, RM; Yellon, DM | 1 |
| Simons, J | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Nissen, SE | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Magalhães, LP; Passos, LC; Rocha, MS; Santana, O; Spósito, AC | 1 |
| Böhm, M; Fries, R | 1 |
| Ashitkov, T; Ballinger, S; Birnbaum, Y; Motamedi, M; Uretsky, BF | 1 |
| Noda, K; Saku, K; Zhang, B | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Magalhães, LP; Passos, LC; Rocha, MS; Spósito, AC | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Ganz, P; Kinlay, S; Leslie, SJ; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Kerrigan, AT | 1 |
| Arikian, S; Ganz, P; Schwartz, GG; Waters, D | 1 |
| Brown, WV; Moussa, M | 1 |
| Guyton, JR; Herrington, DM; McGowan, MP; Shear, C; Waters, DD; Wenger, NK | 1 |
| Blanco-Colio, LM; Egido, J; Osende, JI; Ruiz-Ortega, M | 1 |
| Cannon, CP | 1 |
| Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM | 1 |
| Topol, EJ | 1 |
| Li, J; Xu, Z; Ye, H; Zhao, S; Zhou, H | 1 |
| Chalikias, GK; Chatseras, DI; Hatzinikolaou, EI; Karas, SM; Papadopoulos, ED; Papadopoulou, EG; Parissis, JT; Tentes, IK; Tripsiannis, GA; Tziakas, DN | 1 |
| Berry, DC; Knapp, P; Raynor, DK | 1 |
| Casciano, R; Olsson, A; Stern, L; Svangren, P | 1 |
| Einecke, D | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Pristipino, C; Richichi, G | 1 |
| van der Harst, P; van Veldhuisen, DJ; Voors, AA | 1 |
| LeLorier, J; Paradis, JM | 1 |
| Gotto, AM | 1 |
| Miller, M | 1 |
| Auer, J; Eber, B; Weber, T | 1 |
| Miller, ER; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL | 1 |
| Lange, AP; Szucs, TD | 1 |
| Athyros, VG; Bouloukos, VI; Daskalopoulou, SS; Kakafika, AI; Langer, A; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A | 1 |
| McGowan, MP | 1 |
| Cannon, CP; Ray, KK | 2 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Birnbaum, Y; Hu, ZY; Rosanio, S; Schwarz, ER; Tavackoli, S; Uretsky, BF; Ye, Y | 1 |
| Isley, WL | 1 |
| Casciano, R; Gómez-Gerique, JA; Rejas, J; Stern, L | 1 |
| Farmer, JA | 1 |
| Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Waters, D; Zeiher, A | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Bhatt, DL; Karha, J | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Cheng, X; Cheng, Y; Ge, H; Li, B; Liao, YH; Liu, Y; Lu, B; Wang, M; Yuan, J; Zhang, J | 1 |
| Amasyali, B; Celik, T; Isik, E; Iyisoy, A; Kardesoglu, E; Kilic, S; Kose, S; Kursaklioglu, H | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Iwaniec, T; Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Waters, DD | 1 |
| Liu, HX; Luo, Y; Xie, XM | 1 |
| Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM | 1 |
| Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ; Tsai, J | 1 |
| Atar, S; Birnbaum, Y; Freeberg, SY; Huang, MH; Lin, Y; Nishi, SP; Perez-Polo, JR; Rosanio, S; Uretsky, BF; Ye, Y | 1 |
| Rouleau, J | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Altinbas, A; Aslan, SM; Dede, O; Dogan, A; Ozaydin, M; Ozturk, M; Turker, Y; Varol, E | 1 |
| Atar, S; Birnbaum, Y; Freeberg, SY; Huang, MH; Rahman, AM; Rosanio, S; Uretsky, BF; Ye, Y | 1 |
| Dai, HY; Deng, P; Guan, XS; Huang, HG; Zhao, SP | 1 |
| Clearfield, M | 2 |
| Scheen, AJ | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Deng, P; Hong, SC; Nie, S; Wu, J; Wu, ZH; Zhao, SP; Zhou, HN | 1 |
| Balaraman, R; Bothara, SB; Majithiya, JB; Trivedi, CJ | 1 |
| Atar, S; Birnbaum, Y; Huang, MH; Lin, Y; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Cabrera, F; de Teresa, E; Espinosa, S; García-Pinilla, JM; Gómez-Doblas, JJ; Jiménez-Navarro, MF; Robledo, J; Rodríguez-Bailón, I | 1 |
| Badimon, L; Martínez-González, J | 1 |
| Cheah, JS; Ong, HT | 1 |
| Cayley, WE | 1 |
| Ravnskov, U; Rosch, PJ; Sutter, MC | 1 |
| Mann, SJ | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Kalina, A | 1 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Poli, A; Pujia, A | 1 |
| Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A | 1 |
| Hiasa, Y; Hosokawa, S; Kishi, K; Miyajima, H; Ogata, T; Ogura, R; Ohara, Y; Ohtani, R; Suzuki, N; Takahashi, T; Tomokane, T; Yuba, K | 1 |
| Fitchett, DH; Goodman, SG; Langer, A; Leiter, LA | 1 |
| Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA | 1 |
| Cannon, CP; Ganz, P; Ray, KK | 1 |
| Alhan, CC; Avkaroğullari, M; Cayli, M; Demir, M; Demirtaş, M; Dönmez, Y; Inal, T; Kanadaşi, M; Koç, M; San, M; Usal, A | 1 |
| Chyrchel, M; Dubiel, JS; Dudek, D; Dziewierz, A; Legutko, J; Rakowski, T; Rzeszutko, L | 1 |
| Deshpande, S; Lokhandwala, Y | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Lui, CY; Martinez, JD; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Colonna, G; Di Sciascio, G; Fischetti, D; Miglionico, M; Montinaro, A; Pasceri, V; Patti, G; Sardella, G | 1 |
| Abad, L; Chaves, J; Dueñas, A; Hernandez, G; Pérez-Castrillón, JL; Sanz, A; Vega, G | 1 |
| von Eckardstein, A | 1 |
| Guazzi, M; Guazzi, MD; Reina, G; Tumminello, G; Vicenzi, M | 1 |
| Kulbertus, H | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| deGoma, EM; Fonarow, GC; Rockson, SG | 1 |
| Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Arca, M; Gaspardone, A | 1 |
| Cannon, CP; Kumar, A | 1 |
| Braunwald, E; Buros, J; Cannon, CP; Croce, K; Gao, H; Healy, AM; Libby, P; McCabe, CH; Morrow, DA; Pradhan, AD; Sabatine, MS; Sakuma, M; Simon, DI; Wang, Y | 1 |
| Brännström, M; Bucht, S; Crougneau, V; Dimeny, E; Ekspong, A; Eriksson, M; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Stenlund, H; Wikdahl, AM | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Antoniades, C; Bosinakou, E; Katsi, V; Latsios, G; Marinou, K; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D; Triantafyllou, G; Tsioufis, C; Vavuranakis, E | 1 |
| Aikawa, E; Chen, JW; Figueiredo, JL; Libby, P; Nahrendorf, M; Panizzi, P; Sosnovik, D; Swirski, FK; Weissleder, R | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Abu Said, GH; Birnbaum, Y; Hughes, MG; Lin, Y; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Ye, Y | 1 |
| Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J | 1 |
| Hausenloy, DJ; Riksen, NP; Yellon, DM | 1 |
| Farmer, JA; Jones, PH | 1 |
| Dou, KF; Gao, RL; Geng, YJ; He, ZX; Huang, J; Li, JJ; Lu, MJ; Qian, HY; Shen, R; Yang, GS; Yang, YJ; Zhao, SH | 1 |
| Arnold, M; Daniel, WG; Garlichs, CD; Petzi, S; Raaz, D; Seybold, K; Stumpf, C; Wasmeier, G; Yilmaz, A | 1 |
| Birnbaum, Y; Lin, Y; Martinez, JD; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Sternon, J | 1 |
| Black, D; Chaitman, BR; Ezekowitz, MD; Ganz, P; Kane, JP; Oliver, MF; Olsson, AG; Pressler, ML; Schwartz, GG; Texter, M; Waters, D | 1 |
| Ghali, JK | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Mitka, M | 1 |
| Chaitman, BR; Ezekowitz, MD; Ganz, P; Leslie, S; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, D; Zeiher, A | 1 |
| Sacks, FM | 1 |
| Breen, WJ; Johnson, K | 1 |
| Auer, J; Eber, B | 1 |
| Hsue, PY; Waters, DD | 1 |
| Raggi, P | 1 |
| Welty, FK | 1 |
| Ahsan, CH; Ezekowitz, M; Shah, A | 1 |
| Bastagi, L; Boni, P; Massarelli, G; Muscari, A; Poggiopollini, G; Puddu, P; Tomassetti, V | 1 |
| Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH | 1 |
| Boquist, S; Danell-Toverud, K; Hamsten, A; Karpe, F | 1 |
| Acevedo, M; Francis, G; Lauer, MS; Sprecher, DL | 1 |
| Braga, JC; Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Passos, LC; Rocha, MS; Spósito, AC | 1 |
34 review(s) available for atorvastatin and Cardiovascular Stroke
| Article | Year |
|---|---|
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Rosuvastatin Calcium | 2022 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Effects of adding statins before surgery on mortality and major morbidity: a meta-analysis.
Topics: Adult; Atorvastatin; Cardiac Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Myocardial Infarction; Odds Ratio; Preoperative Care; Publication Bias; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2014 |
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Topics: Acute Kidney Injury; Aged; Atorvastatin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Survival Analysis | 2014 |
Spontaneous coronary artery dissection: the management dilemma continues.
Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazoles; Carvedilol; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Echocardiography; Electrocardiography; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Propanolamines; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2015 |
Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction.
Topics: Animals; Atorvastatin; Chi-Square Distribution; Combined Modality Therapy; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Recovery of Function; Regeneration; Stroke Volume; Time Factors; Ventricular Function, Left | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Spironolactone; Ticlopidine | 2010 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention | 2010 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.
Topics: Atorvastatin; Clinical Trials Data Monitoring Committees; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
The next step in cardiovascular protection.
Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2003 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Safety of high-dose atorvastatin therapy.
Topics: Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2005 |
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stents; Ticlopidine; Time Factors; Vasodilator Agents | 2005 |
[Thoughts about the results of the "IDEAL" study].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine | 2006 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Death, Sudden, Cardiac; Dyslipidemias; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Stroke | 2006 |
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2006 |
Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiology; Clinical Trials as Topic; Continuity of Patient Care; Disease Management; Guideline Adherence; Heptanoic Acids; Hospital Mortality; Hospitalization; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Preventive Medicine; Pyrroles | 2007 |
Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Topics: Angioplasty, Balloon; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Myocardial Ischemia; Pyrroles | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
[Post myocardial infarction management].
Topics: Aftercare; Anticholesteremic Agents; Antioxidants; Atorvastatin; Chromans; Clopidogrel; Diet, Fat-Restricted; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Thiazoles; Thiazolidinediones; Ticlopidine; Troglitazone | 1997 |
Statins revisited.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Naphthalenes; Pyrroles | 1998 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Treatment Outcome | 2001 |
145 trial(s) available for atorvastatin and Cardiovascular Stroke
| Article | Year |
|---|---|
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Topics: Adult; Atherosclerosis; Atorvastatin; Double-Blind Method; Humans; Myocardial Infarction; Oxazolidinones; Treatment Outcome | 2022 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Ramipril; Secondary Prevention | 2022 |
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2023 |
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.
Topics: Adult; Atorvastatin; Cataract; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome; Young Adult | 2023 |
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proteins; Quinazolinones; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2019 |
Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction.
Topics: Angioplasty; Atorvastatin; Biomarkers; Blood Proteins; Chemokines; Female; Galectin 3; Galectins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Proteoglycans; Rosuvastatin Calcium; Treatment Outcome | 2019 |
Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Study.
Topics: Atorvastatin; Heart Failure; Humans; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left | 2020 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cohort Studies; Electrocardiography; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Retrospective Studies; Rosuvastatin Calcium; Tachycardia, Ventricular; Treatment Outcome; Ventricular Function, Left | 2018 |
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Occlusion; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Rosuvastatin Calcium; Surgery, Computer-Assisted; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Topics: Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Care Planning; PCSK9 Inhibitors; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2017 |
Effects of Short-term High Dose Atorvastatin on Left Ventricular Remodeling in Patients with First Time Attack of Anterior Acute Myocardial Infarction.
Topics: Adolescent; Adult; Aged; Atorvastatin; C-Reactive Protein; Drug Administration Schedule; Echocardiography; Endothelin-1; Female; Humans; Male; Malondialdehyde; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Middle Aged; Myocardial Infarction; Ventricular Function, Left; Ventricular Remodeling; Young Adult | 2018 |
Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Combined Modality Therapy; Echocardiography; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Prospective Studies; Pyrroles; Ventricular Function, Left | 2013 |
Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study.
Topics: Aged; Atorvastatin; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Pyrroles; Time Factors | 2013 |
Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiotonic Agents; China; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Premedication; Pyrroles; Reactive Oxygen Species; Severity of Illness Index | 2013 |
Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Topics: Aged; Angina, Stable; Atorvastatin; Elective Surgical Procedures; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?
Topics: Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Placebos; Premedication; Pyrroles | 2014 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period.
Topics: Aged; Angina Pectoris; Antigens, CD; Atorvastatin; C-Reactive Protein; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Progenitor Cells; Female; Heptanoic Acids; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Period; Pyrroles; Troponin I | 2014 |
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2014 |
Patients with stable coronary artery disease receiving chronic statin treatment who are undergoing noncardiac emergency surgery benefit from acute atorvastatin reload.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Cardiac; Disease-Free Survival; Double-Blind Method; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Myocardial Infarction; Postoperative Complications; Preoperative Care; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
[Cardioprotective effect and mechanism of intensive lipid modulation on patients with coronary artery disease undergoing noncardiac surgery].
Topics: Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Brugada Syndrome; Cardiac Conduction System Disease; Coronary Artery Disease; Elective Surgical Procedures; Heart Conduction System; Heptanoic Acids; Humans; Lipids; Myocardial Infarction; Perioperative Period; Pyrroles | 2014 |
Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarc
Topics: Anti-Arrhythmia Agents; Atorvastatin; Benzazepines; Biomarkers; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Emergencies; Femoral Neck Fractures; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Middle Aged; Myocardial Infarction; Orthopedic Procedures; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Research Design; Risk Factors; Severity of Illness Index; Tachycardia, Ventricular; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2014 |
Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Echocardiography; Fatty Acids; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodobenzenes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Pilot Projects; Prospective Studies; Pyrimidines; Pyrroles; Radionuclide Imaging; Rosuvastatin Calcium; Sulfonamides; Thallium; Tomography, Emission-Computed, Single-Photon; Ubiquinone | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Netherlands; Peripheral Arterial Disease; Prospective Studies; Pyrroles; Scandinavian and Nordic Countries; Simvastatin | 2015 |
Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Rosuvastatin Calcium; Treatment Outcome; Turkey | 2015 |
Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells After Percutaneous Coronary Intervention (HIPOCRATES Study).
Topics: Atorvastatin; Cell Count; Dose-Response Relationship, Drug; Endothelial Progenitor Cells; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Stem Cells | 2015 |
[Effect of intensive pretreatment with atorvastatin calcium on outcomes of percutaneous coronary intervention in elderly patients with coronary heart disease].
Topics: Aged, 80 and over; Atorvastatin; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles | 2015 |
Effects of high-dose atorvastatin pretreatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study.
Topics: Adult; Aged; Atorvastatin; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardium; Percutaneous Coronary Intervention; Prospective Studies | 2015 |
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
Dose-dependent effects of atorvastatin on myocardial infarction.
Topics: Adipokines; Atorvastatin; Biomarkers; Blood Glucose; Dose-Response Relationship, Drug; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Russia; Secondary Prevention; Time Factors; Treatment Outcome | 2015 |
Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Angiopoietin-Like Protein 2; Angiopoietin-like Proteins; Angiopoietins; Atorvastatin; Female; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Myocardial Infarction; Oxidative Stress; Prospective Studies; Treatment Outcome; Ventricular Function, Left | 2016 |
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Myocardial Infarction; North America; Predictive Value of Tests; Protective Factors; Reproducibility of Results; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; United Kingdom | 2016 |
Efficacy of High-Intensity Atorvastatin for Asian Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Atorvastatin; China; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipids; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Treatment Outcome; Troponin I | 2016 |
Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Cardiotonic Agents; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Percutaneous Coronary Intervention; Rosuvastatin Calcium; Treatment Outcome | 2016 |
Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
Topics: Aged; Asymptomatic Diseases; Atorvastatin; Biomarkers; Comorbidity; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Prevalence; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2016 |
Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
Topics: Aged; Atorvastatin; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Perioperative Care; Postoperative Complications; Proportional Hazards Models; Risk Assessment; Stroke; Surgical Procedures, Operative; Troponin | 2017 |
Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cell Count; Combined Modality Therapy; Endothelial Cells; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides | 2009 |
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Natriuretic Factor; Cholesterol; Echocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Stroke Volume; Triglycerides; Ventricular Remodeling | 2009 |
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Blood Coagulation; Carotid Artery Diseases; Coronary Disease; Cross-Sectional Studies; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Plasma; Pyrroles; Sample Size; Thrombosis; Ultrasonography | 2009 |
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Myocardial Infarction; Pyrroles; Simvastatin | 2009 |
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Topics: Aged; Atorvastatin; Confounding Factors, Epidemiologic; Drug Prescriptions; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Topics: Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2009 |
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2009 |
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome | 2009 |
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Dose-Response Relationship, Drug; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Pyrroles; Treatment Outcome | 2009 |
Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Pyrroles; Troponin I | 2009 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atorvastatin; Blood Platelets; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Thromboxane A2; Treatment Outcome | 2009 |
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Topics: Angina, Unstable; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Pyrroles | 2009 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Circulation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Korea; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Recurrence; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Italy; Male; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2010 |
Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell mobilisation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Circulation; Cytokines; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Middle Aged; Myocardial Infarction; Neovascularization, Physiologic; Pyrroles; Receptors, CXCR4; Stents; Young Adult | 2010 |
Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplas
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antigens, CD; Atorvastatin; Cadherins; Cell Adhesion Molecules; Chi-Square Distribution; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Italy; Male; Middle Aged; Myocardial Infarction; Myocardium; Placebo Effect; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2010 |
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Topics: Aged; Atorvastatin; Denmark; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Netherlands; Norway; Proportional Hazards Models; Prospective Studies; Pyrroles; Secondary Prevention; Simvastatin; Sweden; Treatment Outcome | 2010 |
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Creatine Kinase, MB Form; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Troponin I | 2011 |
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Retrospective Studies; Stroke; Time Factors | 2011 |
Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; CD4 Antigens; Coronary Vessels; Electrocardiography; Female; Flow Cytometry; Forkhead Transcription Factors; Heptanoic Acids; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Lymphocyte Count; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Treatment Outcome | 2011 |
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2011 |
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Simvastatin; Treatment Outcome | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome | 2011 |
Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chemoprevention; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2011 |
Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
Topics: Aged; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Circulation; Drug Administration Schedule; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardium; Netherlands; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Pilot Projects; Predictive Value of Tests; Pyrroles; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pravastatin; Pregnancy Proteins; Pyrroles; Risk Factors | 2012 |
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke | 2012 |
Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Creatinine; Cystatin C; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Myocardial Infarction; Pyrroles | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome | 2002 |
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Topics: Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Simvastatin; T-Lymphocytes | 2002 |
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate | 2002 |
Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2003 |
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Syndrome; Treatment Outcome | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Topics: Acute Disease; Aged; Angina, Unstable; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pyrroles; Serum Amyloid A Protein; Syndrome; Troponin | 2003 |
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke; Time Factors | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles | 2004 |
Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pyrroles | 2004 |
Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cytokines; Female; Heptanoic Acids; Humans; Male; Matrix Metalloproteinases; Middle Aged; Myocardial Infarction; Pyrroles; Tissue Inhibitor of Metalloproteinases | 2004 |
Comparison of two methods of presenting risk information to patients about the side effects of medicines.
Topics: Adult; Aged; Atorvastatin; Cardiac Surgical Procedures; Communication; Comprehension; Constipation; Drug Information Services; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Pancreatitis; Patient Education as Topic; Physician-Patient Relations; Pyrroles; Risk Assessment; Simvastatin; Terminology as Topic | 2004 |
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Topics: Aged; Angina Pectoris; Angina, Unstable; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomarkers; CD40 Ligand; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pyrroles; Recurrence; Risk; Solubility; Treatment Outcome | 2004 |
Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Biomarkers; Coronary Stenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Myoglobin; Premedication; Prospective Studies; Pyrroles; Stents; Treatment Outcome; Troponin I | 2004 |
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Topics: Aged; Angina, Unstable; Antigen-Antibody Complex; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Autoantibodies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Oxidation-Reduction; Phospholipids; Pyrroles | 2004 |
Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2004 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention | 2005 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Myocardial Infarction; Myocardial Ischemia; Prognosis; Proportional Hazards Models; Pyrroles; Recurrence | 2005 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2004 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
[Effect of atorvastatin on the nuclear factor-kappaB and soluble inter-cellular adhesion molecules-1 in patients with acute coronary syndrome].
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Infarction; NF-kappa B; Pyrroles | 2004 |
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins | 2005 |
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors | 2005 |
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome | 2005 |
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk; Simvastatin | 2005 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Chronotherapy; Coronary Restenosis; Coronary Stenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cyclooxygenase 2; Female; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Myocardial Infarction; Protein C; Pyrroles; RNA, Messenger; Treatment Outcome | 2006 |
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Single-Blind Method; Treatment Outcome | 2006 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
[Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes in patients with acute myocardial infarction and modulates the early inflammatory response].
Topics: Aged; Atorvastatin; Cyclooxygenase 2; Female; Heptanoic Acids; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Myocardial Infarction; Pyrroles; RNA, Messenger | 2005 |
[Effect of statin treatment begun early after acute myocardial infarction on endothelial function in patients with normal levels of cholesterol. VAATOPE Study (VAlue of ATOrvastatin in Postinfarction Endothelium)].
Topics: Aged; Atorvastatin; Brachial Artery; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Pyrroles; Ultrasonography | 2006 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
Prevention of myocardial damage during coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Agents; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction.
Topics: Atorvastatin; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Growth Substances; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Stroke Volume; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Ventricular Function, Left | 2006 |
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors | 2006 |
The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction.
Topics: Acetylcholine; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Vessels; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pyrroles; Regression Analysis; Time Factors | 2006 |
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke | 2006 |
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Syndrome; Time Factors; Treatment Outcome | 2007 |
Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Echocardiography; Exercise Test; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Oxygen Consumption; Pyrroles | 2007 |
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Topics: Acute Coronary Syndrome; Aged; Anti-Infective Agents; Atorvastatin; Biomarkers; Calgranulin A; Calgranulin B; Case-Control Studies; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Probability; Pyrroles; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Treatment Outcome | 2008 |
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Myocardial Infarction; Prospective Studies; Pyrroles | 2005 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Topics: Atorvastatin; Biomarkers; Electrocardiography; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pyrroles; Time Factors; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2009 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Research Design | 1998 |
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Recurrence; Survival Analysis | 2001 |
Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Health Behavior; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Primary Prevention; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men.
Topics: Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Cholesterol, HDL; Complement C3c; Double-Blind Method; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Vitamin E | 2001 |
Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipids; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Postprandial Period; Pyrroles; Sweden; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome; Triglycerides | 2002 |
189 other study(ies) available for atorvastatin and Cardiovascular Stroke
| Article | Year |
|---|---|
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2023 |
Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI).
Topics: Amiodarone; Atorvastatin; Cardiovascular Agents; Case-Control Studies; China; Creatine Kinase, MB Form; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Random Allocation; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2021 |
Atorvastatin-induced tolerogenic dendritic cells improve cardiac remodeling by suppressing TLR-4/NF-κB activation after myocardial infarction.
Topics: Animals; Apoptosis; Atorvastatin; Cytokines; Dendritic Cells; Disease Models, Animal; Fibrosis; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; NF-kappa B; Stroke Volume; Toll-Like Receptor 4; Ventricular Function, Left; Ventricular Remodeling | 2023 |
Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway.
Topics: Animals; Atorvastatin; Extracellular Vesicles; Macrophages; Mesenchymal Stem Cells; MicroRNAs; Myocardial Infarction; Rats; STAT1 Transcription Factor | 2023 |
Effect of new cardiac rehabilitation mode on cardiac function, mental state and quality of life of postoperative patients with acute myocardial infarction treated with atorvastatin calcium tablet.
Topics: Atorvastatin; Cardiac Rehabilitation; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Quality of Life; Treatment Outcome | 2023 |
[Severe rhabdomyolysis associated with atorvastatin. Case report].
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Rhabdomyolysis; Risk Factors | 2023 |
Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction.
Topics: Atorvastatin; Coronary Angiography; Coronary Circulation; Humans; Microcirculation; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Retrospective Studies; Rosuvastatin Calcium; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Atorvastatin improves the cardiac function of rats after acute myocardial infarction through ERK1/2 pathway.
Topics: Acute Disease; Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Echocardiography; Heart Function Tests; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Rats; Rats, Sprague-Dawley | 2019 |
Pharmacology of atorvastatin on myocardial ischemia-reperfusion in rats and drug effect analysis.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Female; Male; Myocardial Infarction; Myocardial Ischemia; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2019 |
Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Female; Gastroesophageal Reflux; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Rosuvastatin Calcium; Treatment Outcome; Triglycerides | 2020 |
Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany.
Topics: Age Factors; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Cross-Sectional Studies; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Simvastatin; Tertiary Care Centers; Tertiary Healthcare | 2020 |
Effects of atorvastatin combined with bivalirudin on coagulation function, cardiac function, and inflammatory factors of percutaneous coronary intervention in elderly patients with acute myocardial infarction.
Topics: Acute Disease; Aged; Atorvastatin; Blood Coagulation; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2020 |
Unexpected Troponin Elevation in a Patient Treated with Atorvastatin.
Topics: Aged; Atorvastatin; Diagnosis, Differential; Drug Hypersensitivity; False Positive Reactions; Female; Humans; Myocardial Infarction; Troponin I; Troponin T | 2020 |
Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; HMGB Proteins; HMGB1 Protein; Humans; Myocardial Infarction; Prospective Studies | 2021 |
Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries.
Topics: Aged; Aged, 80 and over; Atorvastatin; Black or African American; Cohort Studies; Female; Hispanic or Latino; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medicare; Medication Adherence; Myocardial Infarction; Retrospective Studies; Rosuvastatin Calcium; Secondary Prevention; United States; White People | 2017 |
Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxidative Stress; Pilot Projects; Rosuvastatin Calcium | 2017 |
Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014.
Topics: Aged; Atorvastatin; Dose-Response Relationship, Drug; Drug Prescriptions; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Discharge; Retrospective Studies; Time Factors; Treatment Outcome | 2017 |
[Role of atorvastatin in improving the inflammation-induced adipokine imbalance in mice with acute myocardial infarction].
Topics: Adipokines; Adiponectin; Animals; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Gene Expression; Inflammation; Mice; Mice, Inbred C57BL; Myocardial Infarction; Resistin | 2017 |
Galectin-3 in patients with coronary heart disease and atrial fibrillation.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Blood Proteins; Catheter Ablation; Coronary Disease; Female; Fibrosis; Galectin 3; Galectins; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Severity of Illness Index; Stroke Volume | 2018 |
Atorvastatin Attenuates Metabolic Remodeling in Ischemic Myocardium through the Downregulation of UCP2 Expression.
Topics: Angiotensin II; Animals; Atorvastatin; Coronary Vessels; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Rats; Uncoupling Protein 2 | 2018 |
The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase, MB Form; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Regression Analysis; Time Factors; Triglycerides; Troponin T | 2019 |
Paradoxical effects of atorvastatin in isoproterenol-induced cardiotoxicity in rats: Role of oxidative stress and inflammation.
Topics: Animals; Antioxidants; Atorvastatin; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Heart; Inflammation; Isoproterenol; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Rats; Rats, Wistar | 2018 |
Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus.
Topics: Administrative Claims, Healthcare; Aged; Atorvastatin; Biomarkers; Databases, Factual; Diabetes Mellitus; Drug Prescriptions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Medicare Part D; Myocardial Infarction; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Time Factors; Treatment Outcome; United States | 2018 |
Panax Quinquefolium Saponins Attenuate Myocardial Dysfunction Induced by Chronic Ischemia.
Topics: Animals; Arterioles; Atorvastatin; Chromatography, High Pressure Liquid; Chronic Disease; Coronary Stenosis; Down-Regulation; Echocardiography; Glucose; Heart; Mass Spectrometry; Myocardial Infarction; Myocardium; Positron-Emission Tomography; Proteome; Proteomics; Saponins; Swine; Up-Regulation; Ventricular Function | 2018 |
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction.
Topics: Atorvastatin; Biomarkers; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Quinolines; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium | 2018 |
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Registries; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; ST Elevation Myocardial Infarction; Tertiary Care Centers; Time Factors | 2019 |
Statins and myocardial infarction: from secondary 'prevention' to early 'treatment'.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Percutaneous Coronary Intervention; Secondary Prevention; ST Elevation Myocardial Infarction | 2019 |
Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19.
Topics: Angiogenic Proteins; Animals; Apoptosis; Atorvastatin; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Endothelial Cells; Exosomes; Female; Humans; Inflammation Mediators; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Rats, Sprague-Dawley; Recovery of Function; RNA, Long Noncoding; Up-Regulation; Ventricular Function, Left | 2020 |
Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction.
Topics: Acute Disease; Animals; Atorvastatin; Disease Models, Animal; Humans; Male; Mesenchymal Stem Cells; Myocardial Infarction; Rats; Time Factors | 2019 |
Atorvastatin improves cardiac function of mice with acute myocardial infarction by interfering in macrophages to activate mitogen-activated protein kinase pathway.
Topics: Animals; Atorvastatin; Macrophages; Mice; Mitogen-Activated Protein Kinases; Myocardial Infarction | 2021 |
Exosomes and non-coding RNA, the healers of the heart?
Topics: Atorvastatin; Exosomes; Humans; Mesenchymal Stem Cells; Myocardial Infarction; RNA, Long Noncoding | 2020 |
Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries.
Topics: Aftercare; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Correlation of Data; Drug Utilization; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medicare; Myocardial Infarction; Patient Discharge; Retrospective Studies; Rosuvastatin Calcium; United States | 2019 |
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids; Humans; Male; Methotrexate; Middle Aged; Myocardial Infarction; Omeprazole; Polymyositis; Prednisone; Proton Pump Inhibitors; Pyrroles; Treatment Outcome; Withholding Treatment | 2013 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study.
Topics: Aged; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Myocardial Infarction; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2013 |
Hepatitis B virus reactivation associated with atorvastatin.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Cholesterol, LDL; Hepatitis B; Hepatitis B virus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Viral Load; Virus Activation; Virus Replication | 2013 |
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
Topics: Animals; Apoptosis; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Swine; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2013 |
Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
Topics: Animals; Atorvastatin; Collagen; Disease Models, Animal; Female; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Ventricular Remodeling | 2013 |
Atorvastatin improves microenvironment to enhance the beneficial effects of BMSCs therapy in a rabbit model of acute myocardial infarction.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocytes, Cardiac; Pyrroles; Rabbits | 2013 |
Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Occlusion; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunohistochemistry; Inflammation; Interferon-gamma; Interleukin-6; Ligation; Male; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Necrosis; No-Reflow Phenomenon; Pyrroles; Rabbits; Random Allocation | 2014 |
Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
Topics: Analysis of Variance; Angina, Unstable; Atorvastatin; Cohort Studies; Drug Prescriptions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Israel; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction: the role of the RhoA/ROCK/ERK pathway.
Topics: Animals; Atorvastatin; Cells, Cultured; Female; Heptanoic Acids; Male; MAP Kinase Signaling System; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; rhoA GTP-Binding Protein; Treatment Outcome; Ultrasonography | 2014 |
Atorvastatin administered before myocardial infarction in rats improves contractility irrespective of metabolic changes.
Topics: Animals; Atorvastatin; Echocardiography; Glucose Transporter Type 4; Heart Ventricles; Heptanoic Acids; Male; Muscle Contraction; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Inbred WKY; Ventricular Remodeling | 2014 |
Atorvastatin at reperfusion reduces myocardial infarct size in mice by activating eNOS in bone marrow-derived cells.
Topics: Animals; Atorvastatin; Bone Marrow Cells; Bone Marrow Transplantation; Cardiotonic Agents; Drug Evaluation, Preclinical; Enzyme Activation; Heart Ventricles; Male; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Neutrophil Infiltration; Nitric Oxide Synthase Type III | 2014 |
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin | 2015 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Pre-treatment of a single high-dose of atorvastatin provided cardioprotection in different ischaemia/reperfusion models via activating mitochondrial KATP channel.
Topics: Animals; Atorvastatin; Calcium; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Heart Ventricles; Hemodynamics; L-Lactate Dehydrogenase; Male; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen; Potassium Channels; Rats; Reactive Oxygen Species; Risk | 2015 |
Endothelial Progenitor Cells and Percutaneous Coronary Artery Intervention : Editorial to: "Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells after Percutaneous Coronary Intervention (HIPOCRATES Study)" by A. Eisen et al.
Topics: Atorvastatin; Endothelial Progenitor Cells; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2015 |
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand; Treatment Outcome | 2015 |
Protocols cure diseases, not patients: flaccid paresis in post-NSTEMI statin treatment.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Atorvastatin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Paresis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Rhabdomyolysis; Stents | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Blood Glucose; Cardiotonic Agents; Catalase; Cholesterol; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necrosis; Pravastatin; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Superoxide Dismutase; Triglycerides | 2015 |
Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2015 |
Interindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction.
Topics: Aged; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Peroxidase; Triglycerides | 2016 |
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism.
Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female; Humans; Myocardial Bridging; Myocardial Infarction; Perindopril; Ticlopidine; Treatment Outcome; Vascular Diseases | 2016 |
Atorvastatin Inhibits Myocardial Apoptosis in a Swine Model of Coronary Microembolization by Regulating PTEN/PI3K/Akt Signaling Pathway.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Down-Regulation; Echocardiography; Embolism; Myocardial Infarction; Myocardium; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; RNA, Small Interfering; Signal Transduction; Swine; Troponin I | 2016 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
Inflammation Activation Contributes to Adipokine Imbalance in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adipokines; Adiponectin; Animals; Atorvastatin; Blotting, Western; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Middle Aged; Myocardial Infarction; Resistin | 2016 |
[Statins according to individual risk].
Topics: Aged; Atorvastatin; Cholesterol, LDL; General Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Middle Aged; Myocardial Infarction; Risk | 2016 |
Atorvastatin attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats postmyocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arginase; Atorvastatin; Cells, Cultured; Disease Models, Animal; GAP-43 Protein; Heart; Interleukin-1beta; Macrophage Activation; Macrophages, Peritoneal; Male; Myocardial Infarction; Myocardium; Nerve Growth Factor; Nitric Oxide Synthase Type II; Phenotype; Rats, Wistar; Sympathetic Nervous System; Tachycardia, Ventricular; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase; Ventricular Fibrillation | 2016 |
Atorvastatin alleviates cardiomyocyte apoptosis by suppressing TRB3 induced by acute myocardial infarction and hypoxia.
Topics: Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Myocardial Infarction; Myocytes, Cardiac; Protein Serine-Threonine Kinases; Rats; Rats, Wistar | 2017 |
Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
Topics: Adolescent; Atorvastatin; Blood Component Removal; Bradykinin; Child; Child, Preschool; Decision Making; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Infant; Lipoproteins; Myocardial Infarction; Patient Compliance; Pregnancy; Pregnancy Complications, Cardiovascular; Treatment Outcome; Young Adult | 2016 |
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
Topics: Acute Coronary Syndrome; Aged; American Heart Association; Angina, Unstable; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Female; Guideline Adherence; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Societies, Medical; Stroke; United States | 2016 |
Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Catheter Ablation; Collagen; Disease Models, Animal; Fibrosis; Gene Expression; Heart Ventricles; Hemodynamics; Interleukin-1; Male; Matrix Metalloproteinase 1; Myocardial Infarction; Myocardium; NF-kappa B p50 Subunit; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Ventricular Remodeling | 2016 |
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Stroke | 2017 |
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Atorvastatin; Benzaldehydes; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Oximes; Phospholipase A2 Inhibitors; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosuvastatin Calcium; Secondary Prevention; Sex Factors; Simvastatin | 2017 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Echocardiography; Heptanoic Acids; Hypercholesterolemia; Losartan; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
Advertisements for atorvastatin were misleading to women.
Topics: Advertising; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Sex Factors | 2008 |
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
Topics: Adult; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
[Intensive atorvastatin therapy in patients with acute myocardial infarction].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome | 2008 |
[High dosage stain protects heart and brain from recurrence].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2008 |
Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats.
Topics: Animals; Atorvastatin; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tumor Necrosis Factor-alpha; Ventricular Function | 2009 |
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.
Topics: Animals; Atorvastatin; Body Weight; Cardiac Volume; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2010 |
Right ventricular function in ST elevation myocardial infarction: effect of reperfusion.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Female; Heptanoic Acids; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Pyrroles; Streptokinase; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Ventricular Function, Right | 2009 |
Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin.
Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Myocardial Infarction; Osteogenesis; Pyrroles; Treatment Outcome | 2010 |
Headache as the sole presenting symptom of acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Headache; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Oxygen Inhalation Therapy; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2009 |
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Binding, Competitive; Cells, Cultured; Contrast Media; Disease Models, Animal; Endothelium, Vascular; Feasibility Studies; Fluorodeoxyglucose F18; Graft Rejection; Half-Life; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Iopamidol; Ligands; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Peptides; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; RNA, Messenger; Tissue Distribution; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2009 |
Marrow-derived MSCs and atorvastatin improve cardiac function in rat model of AMI.
Topics: Animals; Atorvastatin; Bone Marrow; Combined Modality Therapy; Disease Models, Animal; Heptanoic Acids; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Ventricular Function | 2011 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States | 2010 |
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Models, Theoretical; Myocardial Infarction; Placebos; Pyrroles; Risk Factors; Secondary Prevention; Spain; Stroke; Treatment Outcome; Young Adult | 2010 |
Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Topics: Adult; Alleles; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol 7-alpha-Hydroxylase; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Polymorphism, Single Nucleotide; Pyrroles; Triglycerides | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical Analysis; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Education, Medical, Continuing; Electroencephalography; Family Practice; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pyrroles; Risk Factors; Switzerland; Ticlopidine | 2010 |
Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure.
Topics: Animals; Atorvastatin; Cells, Cultured; Heart Failure; Heptanoic Acids; Lung; Myocardial Infarction; Myofibroblasts; Pyrroles; Random Allocation; Rats; Respiratory Function Tests | 2010 |
Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Electrocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pyrroles; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2010 |
Atorvastatin for reduction of myocardial damage during angioplasty trials.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clopidogrel; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardium; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2010 |
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Statistics as Topic | 2011 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kidney Diseases; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.
Topics: Adult; Aged; Antigens, CD34; Atorvastatin; Biomarkers; Coronary Artery Disease; Endothelial Cells; Female; Flow Cytometry; Hematology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Evidence-Based Medicine; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Myocardial Infarction; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 12; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Heart Failure; Heat-Shock Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Myocardial Infarction; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Wistar; Transcription Factor CHOP | 2011 |
Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction.
Topics: Animals; Apoptosis; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Muscle Contraction; Myocardial Infarction; Myocytes, Cardiac; Pyrroles; Rats; Rats, Inbred F344; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction.
Topics: Adipose Tissue; Animals; Atorvastatin; bcl-2-Associated X Protein; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Disease Models, Animal; GATA4 Transcription Factor; Heart Function Tests; Heptanoic Acids; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rats; Rats, Sprague-Dawley; Troponin I; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2011 |
Myocardial infarction in an young patient associated with oral contraceptive, smoking and elevated cholesterol level.
Topics: Abortion, Induced; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Clopidogrel; Contraceptives, Oral; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pregnancy; Pyrroles; Smoking; Ticlopidine | 2012 |
[Effect of atorvastatin on cardiac function and TGF-β1 signaling pathway after acute myocardial infarction in rats].
Topics: Animals; Atorvastatin; Heart; Heptanoic Acids; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1; Ventricular Remodeling | 2012 |
Ask the doctor. After a heart attack six years ago, I went on Lipitor (atorvastatin) because my doctor said it was proven to reduce the risk of a second heart attack in high-risk people like me. Three years ago, I switched to a generic (simvastatin) to sa
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Effects of acute and chronic atorvastatin on cardioprotection of ischemic postconditioning in isolated rat hearts.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Drug Administration Schedule; Hemodynamics; Heptanoic Acids; In Vitro Techniques; Ischemic Postconditioning; Male; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Time Factors | 2013 |
Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study.
Topics: Adult; Aged; Atorvastatin; Cell Movement; Chemokine CXCL12; Dipeptidyl Peptidase 4; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardium; Pyrroles | 2012 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Statin pleiotropy in acute myocardial infarction--is it about timing?
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles | 2012 |
SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Atorvastatin; Benzylamines; Chemokine CXCL12; Coronary Vessels; Cyclams; Heptanoic Acids; Heterocyclic Compounds; Ligation; Male; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; STAT3 Transcription Factor; Up-Regulation | 2012 |
Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Drug Resistance; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pakistan; Polymorphism, Single Nucleotide; Pyrroles; Risk; RNA, Long Noncoding; Sequence Analysis, DNA; Triglycerides | 2013 |
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.
Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
[Maintaining the full benefit of statins. Therapy start 10 years earlier?].
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2002 |
Causal structures for evaluating statin class effects.
Topics: Atorvastatin; Biomarkers; Cholesterol, LDL; Drug Costs; Drug Prescriptions; Formularies as Topic; Health Maintenance Organizations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Risk | 2002 |
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Europe; Guideline Adherence; Heptanoic Acids; Humans; Myocardial Infarction; Practice Guidelines as Topic; Preventive Health Services; Pyrroles; Societies; Stroke; United Kingdom | 2002 |
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyrroles; Reperfusion; Signal Transduction; Time Factors; Up-Regulation | 2003 |
The $10 billion pill.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Design; Drug Industry; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; United States | 2003 |
Reduction of infarct size by short-term pretreatment with atorvastatin.
Topics: Animals; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NG-Nitroarginine Methyl Ester; Pyrroles; Rats; Rats, Sprague-Dawley | 2003 |
Effect of atorvastatin on total lipid profiles assessed by analytical capillary isotachophoresis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Protein Electrophoresis; Electrophoresis, Capillary; Follow-Up Studies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Male; Myocardial Infarction; Pyrroles | 2003 |
No absolutes.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Risk; Sample Size | 2003 |
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Cost-Benefit Analysis; Economics, Pharmaceutical; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Secondary Prevention; Syndrome | 2003 |
[Following the ASCOT Study. A statin for every hypertensive patient?].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Treatment Outcome | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Intensive statin therapy--a sea change in cardiovascular prevention.
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Lipitor bests Pravachol at certain doses.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2004 |
Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
"Major surprise" in a new study means likely changes in treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Health Care Costs; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Retrospective Studies; Sweden; Syndrome; Time Factors; Treatment Outcome | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
New LDL goals: even lower?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Secondary Prevention | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
[Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
Topics: Acute Disease; Adolescent; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analysis; Diagnosis-Related Groups; Double-Blind Method; Germany; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Patient Compliance; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Syndrome; Time Factors | 2004 |
Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Biological Availability; Capillaries; Cells, Cultured; Collateral Circulation; Drug Resistance; Endothelial Cells; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Random Allocation; Ultrasonography; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2004 |
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury.
Topics: Animals; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intramolecular Oxidoreductases; Isoxazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phospholipases A; Phospholipases A2; Phosphorylation; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2005 |
What did PROVE-IT prove?
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy | 2004 |
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Cost Savings; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Economics, Pharmaceutical; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Spain; Syndrome; Time Factors; Treatment Outcome | 2004 |
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction.
Topics: Atorvastatin; Cells, Cultured; Disease Progression; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lymphocyte Activation; Male; Middle Aged; Myocardial Infarction; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer | 2005 |
The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Circulation; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Retrospective Studies; Stroke Volume; Treatment Outcome | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease.
Topics: Alleles; Angiography; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Blood Pressure; Coronary Artery Disease; Fibrin Fibrinogen Degradation Products; Genotype; Hemostasis; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Pyrroles; Quinapril; Risk; Tetrahydroisoquinolines; Time Factors | 2005 |
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome | 2005 |
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Heart; Heptanoic Acids; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardium; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2006 |
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Infections; Male; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin.
Topics: Amidines; Animals; Atorvastatin; Benzylamines; Cardiotonic Agents; Drug Synergism; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase Inhibitors; Phosphorylation; Piperazines; Purines; Pyrroles; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Up-Regulation | 2006 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Effect of atorvastatin treatment on isoproterenol-induced myocardial infarction in rats.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Body Weight; Catalase; Glutathione; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Lipid Peroxidation; Male; Myocardial Infarction; Myocardium; Necrosis; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2006 |
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Heptanoic Acids; Hypoglycemic Agents; Inositol Polyphosphate 5-Phosphatases; Male; Myocardial Infarction; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Phospholipases A; Phospholipases A2; Phosphoric Monoester Hydrolases; Phosphorylation; Pioglitazone; PTEN Phosphohydrolase; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazolidinediones | 2006 |
[Early effect of statins after myocardial infarction. A statin-induced pleiotropic effect?].
Topics: Atorvastatin; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Pyrroles | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Endpoint Determination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results | 2006 |
The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Serum Amyloid A Protein; Statistics as Topic; Syndrome; Treatment Outcome; Triglycerides | 2006 |
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Premedication; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2006 |
API expert consensus document on management of ischemic heart disease.
Topics: Angioplasty; Atorvastatin; Clinical Trials as Topic; Coronary Angiography; Drug Costs; Dyslipidemias; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Myocardial Infarction; Pyrroles; Streptokinase; Thrombolytic Therapy | 2006 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2007 |
Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease.
Topics: Aged; Angina, Unstable; Atorvastatin; Calcifediol; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Networks and Pathways; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome; Triglycerides; Vitamin D; Vitamin D Deficiency | 2007 |
[Hypercholesterolemia and control with therapy].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diagnosis, Differential; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Pyrroles; Treatment Refusal; Triglycerides | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
Higher dose of statin medication may be better for older adults.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Stroke | 2007 |
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Gadolinium; Heptanoic Acids; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Peroxidase; Pyrroles | 2008 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Pressure; Caffeine; Coffee; Disease Models, Animal; Food-Drug Interactions; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1 | 2008 |
Lipid levels after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides | 2008 |
Wake up and smell the coffee: yet another no go for cardiac patients? : editorial to "caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat" by Ye et al.
Topics: Administration, Oral; Animals; Atorvastatin; Caffeine; Coffee; Food-Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats | 2008 |
Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Cell Differentiation; Combined Modality Therapy; Cytokines; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Angiography; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Oxidative Stress; Pyrroles; Survival Rate; Swine; Swine, Miniature; Tomography, Emission-Computed, Single-Photon | 2008 |
Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
Topics: Animals; Atorvastatin; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-10; Macrophages; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Atorvastatin; Cyclooxygenase 2; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptides; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tyrphostins; Up-Regulation | 2008 |
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome | 1998 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Fast, aggressive treatment for myocardial infarction urged.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Stents; Tirofiban; Tyrosine | 2000 |
Lipid-lowering therapy in acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Infarction; Pyrroles | 2001 |
[Decreasing blood lipids for prevention of coronary heart disease--discussion of the "permissive LDL level". Diagnostic imaging facilitates therapeutic decision].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diagnostic Imaging; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Treatment Outcome | 2001 |
[Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Risk Factors; Survival Rate | 2001 |
Can early treatment with atorvastatin (Lipitor) improve the outcome of patients with acute coronary syndromes?
Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Controlled Clinical Trials as Topic; Double-Blind Method; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Time Factors | 2001 |
The use of electron-beam computed tomography as a tool for primary prevention.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Mass Screening; Middle Aged; Myocardial Infarction; Pyrroles; Tomography, X-Ray Computed | 2001 |
Women and cardiovascular risk.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Sex Factors; Survival Rate | 2001 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2002 |
Routine statin treatment after acute coronary syndromes?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Patient Discharge; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2002 |